Kiadis Pharma N.V.
Below you will find information from the register publication of inside information. The information has been provided by the organisation.
- Registration date 30 sep 2015 - 07:00
- Statutory name Kiadis Pharma N.V.
- Title Kiadis Pharma announces initiation of a repeat-dosing Phase II clinical trial with ATIR101™
- Comments Amsterdam, The Netherlands, September 30, 2015 – Kiadis Pharma N.V. (“Kiadis Pharma” or “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that it has obtained regulatory approvals from the national authorities both in Canada and in Belgium to start a further Phase II clinical trial with its lead product ATIR101™. In this new trial the safety and efficacy of using a second dose of ATIR101™ will be studied (NCT02500550 / EudraCT 2015-002821-20).
|201509290000000010_PR Kiadis Pharma Initiation 008 trial 2015-09-30.docx|
|201509290000000010_PR Kiadis Pharma Initiation 008 trial 2015-09-30.pdf|
Date last update: 06 December 2021